Study of ASP2138 before surgery for pancreatic cancer
Treatments studied
Part of Cancer clinical trials.
This study tests an experimental drug, ASP2138, given before surgery for pancreatic cancer that is still removable. After surgery, you will receive standard chemotherapy. The goal is to see if adding ASP2138 before surgery helps improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your pancreatic cancer must be the type that can be removed with surgery, and you must not have had any treatment for it yet.
- Your tumor must test positive for a protein called claudin 18.2 (CLDN18.2), which the study drug targets.
- You must be able to have surgery and then chemotherapy after surgery, as part of your standard care.
- You should be in generally good health (able to do most daily activities) and have no serious heart problems in the last 6 months.
- Women who could become pregnant must use effective birth control for 6 months after the last dose of the study drug, and men must also use contraception.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests giving chemotherapy plus pembrolizumab (an immunotherapy) before surgery, to shrink or control potentially removable pancreatic cancer. The goal is to improve outcomes while making sure the cancer can still be safely removed by surgery.
This study looks at specific body chemistry pathways in pancreatic cancer tissue to better understand what may help treatment work. If you are having pancreatic surgery, the researchers will take extra small tissue samples during the operation to study tumor and normal tissue.
This trial tests a new treatment that uses light to activate a drug attached to cancer cells, aiming to destroy them during surgery. It is for people with pancreatic cancer that has not spread and who have already had chemotherapy.
This Phase 1 trial tests ASP2138 alone or with other cancer medicines in adults with stomach (including GEJ) or pancreatic cancer. You may be eligible if your tumor has a specific protein marker and your health tests and scan results meet safety requirements.
This Phase 2 trial tests a chemotherapy plan given before surgery (called “neoadjuvant” treatment) for people with pancreatic adenocarcinoma that looks resectable or borderline resectable on scans. The goal is to see how well this adaptive chemotherapy approach works and whether it can improve outcomes before an operation.
This trial tests whether giving treatment before surgery helps people with pancreatic cancer that can be removed. The treatment is given before the operation, and the study checks if it is safe and effective.
Hear when a new Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.